44 acuerdos. $53.2B.
Los ADC de China están redefiniendo la oncología global.

De licencias individuales ➡️ alianzas de plataformas.
Big Pharma se mueve rápido.

¿Qué significa para el futuro del cáncer?

🎥 Mira el análisis 👇

#ADC #Biotech #Oncología #Pharma #ChinaBiotech #DengYueMed

Sanofi’s $1.53 Billion China Bet Signals a New Map for Biotech Innovation - Biotech Industry Examiner The rovadicitinib deal is about more than one blood-cancer and transplant asset. It is another sign that global pharma is no longer treating China mainly as a

China is no longer just a biotech market. It is increasingly a source of licensable innovation for global pharma.

Sanofi’s up-to-$1.53B rovadicitinib deal is the latest signal — and part of a much bigger shift in where drug innovation begins.

#Biotech #Pharma #ChinaBiotech #BiotechNews #TechNews

The narrative has officially shifted: China is no longer a "fast-follower"—it has become the global engine for First-in-Human (FIH) innovation.As an investor, three data points from this report stand out as strategic signals for the year ahead: 1. The Efficiency Moat: Since 2021, China has registered nearly twice as many FIH trials for next-gen antibodies (ADCs, bispecifics) as the U.S. and Europe combined. In an era where "speed to data" is everything, China’s clinical infrastructure is delivering results at a fraction of the cost. 2. From "Me-Too" to "High-Complexity": Modality mix is evolving rapidly. In 2025, cell and gene therapies (CGT) and nucleic acid assets accounted for 50% of deal volume in China. We are seeing a massive shift toward high-complexity assets that global MNCs are eager to integrate into their pipelines. 3. The Arbitrage Opportunity: Western pharmas are essentially "acquiring de-risked innovation hubs" via licensing rather than full M&A. With U.S. early-stage assets facing funding constraints, the cross-border licensing of underfunded but clinically superior Chinese assets is the most capital-efficient way to bridge the "patent cliff." My Take: The "China Edge" is likely to persist for years. The massive spike in innovative drug submissions—from 688 in 2019 to nearly 2,300 in 2023—is just now reaching the peak of its value realization. For LPs and GPs, the question isn't whether to have exposure to China-originated assets, but how to structure the partnerships to navigate the geopolitical noise while capturing the scientific alpha. Source: [https://lnkd.in/ezEfyWRm](https://lnkd.in/ezEfyWRm)

Why China’s early-stage drugmaking edge is the most compelling “de-risked” opportunity in 2026.

The latest Pitchbook analyst note on the Chinese biopharma landscape is a wake-up call for global asset allocators.

#BCIC #VentureCapital #Pitchbook #ChinaBiotech #AssetAllocation #CGT #ADC

China Biobanking Market Growth & Opportunities 2035 China Biobanking Market share register 5.28 USD Billion in 2024, projected to grow 4.12 % CAGR to reach USD Billion 8.23 during the forecast period 2025 - 2035.

🇨🇳🧫 China Biobanking Market growth analysis 👉 www.marketresearchfuture.com/reports/chin... #Biobanking #ChinaBiotech #LifeSciences

China Gene Editing Market Size, Share, Trends, Report 2035 China Gene Editing Market share register 608.30 USD Million in 2024, projected to grow 20.94 % CAGR to reach USD Million 4926 during the forecast period 2025 - 2035.

🇨🇳🧬 China Gene Editing Market insights 👉 www.marketresearchfuture.com/reports/chin... #GeneEditing #CRISPR #ChinaBiotech

China Antibodies Market Size, Share, Trends, Forecast 2035 China Antibodies Market share register 22.84 USD Billion in 2024, projected to grow 13.72 % CAGR to reach USD Billion 94 during the forecast period 2025 - 2035.

🇨🇳🧪 China Antibodies Market research highlights 👉 www.marketresearchfuture.com/reports/chin... #Antibodies #ChinaBiotech #Healthcare

China Pushes Boundaries With Animal Testing to Win Global Biotech Race China is accelerating its biotech ambitions by pushing the limits of animal testing and gene editing (source paywalled; alternative source) while Western countries tighten ethical restrictions.

China Pushes Boundaries With Animal Testing to Win Global Biotech Race #Technology #Business #Other #BiotechInnovation #AnimalTesting #ChinaBiotech

China Preclinical Imaging Market Size, Growth Report 2035 China Preclinical Imaging Market Industry is expected to grow from 372.75(USD Million) in 2024 to 992.9 (USD Million) by 2035. The China Preclinical Imaging Market CAGR (growth rate) is expected to be...

🔬 Innovation before intervention! China’s #PreclinicalImaging grows with cutting-edge models & AI visualization.
#BiomedicalResearch #ChinaBiotech #DrugPipeline #3DImaging

www.marketresearchfuture.com/reports/chin...

China biotech rally seen as too rapid, investors shift to clinical CROs - Macquarie Investing.com - The recent rally in Hong Kong-listed biotechs, fueled by fund flows and outlicensing expectations, has been too rapid according to investors, with focus now shifting to clinical research organizations (CROs), Macquarie reports. Macquarie analysts note that the recent biotech rally has primarily benefited thinly-traded small caps, deviating from traditional biotech investing which typically focuses on pipeline developments and regulatory catalysts. While China biopharma outlicensing has attracted generalist investors due to high-profile deals, Macquarie cautions that predicting which companies will secure valuable licensing deals is "exceedingly difficult, if not impossible." The firm highlights that most licensing deals from Chinese companies are small in value and rarely affect licensors’ long-term financial performance. Additionally, most outlicensed assets ultimately fail in clinical trials, regulatory review, or commercial launch, further complicating investment decisions in the sector. China’s domestic environment remains challenging for most biopharmacos, with tight national insurance budgets, price-cutting schemes, and anti-corruption campaigns creating ongoing pressure. Macquarie does not expect these conditions to improve soon, recommending investors focus on proven long-term biotechs instead. In response to market conditions, Macquarie has adjusted its recommendations, now favoring Hansoh at the top position, followed by BeOne and Akeso in dual second place. The firm notes that some investors now view clinical trial outsourcing CROs as potential beneficiaries of licensing deals and the reopening of Hong Kong’s IPO window. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Biotech #ChinaBiotech #Investing #ClinicalResearch #CROs

Lab to label? Not always.
BioNTech sold a cancer drug to BMS for $11B—originally bought from China’s Biotheus for $800M.
Early exit, or a system that leaves no better choice?
#ChinaBiotech #PharmaDeals #Econsky

China Biochips Market Size, Growth Outlook 2035 China Biochips Market growth is projected to reach 2.5 USD billion, at a 8.687% CAGR by driving size, share, top company analysis, segments research, trends and forecast report 2025 to 2035.

🧬 Innovation on chip! China is revolutionizing diagnostics through biochips. 🇨🇳🔍
#Biochips #ChinaBiotech #GenomicTesting #LabOnChip

www.marketresearchfuture.com/reports/chin...